Martin Wilson, who serves as General Counsel at ROCKET PHARMACEUTICALS, INC. (NASDAQ:RCKT), executed a transaction on May 13, 2026, involving the sale of company common stock.
Specifically, Mr. Wilson sold 3,361 shares of RCKT's common stock. The total value derived from this divestment amounted to $12,119, with each share being purchased at a price point of $3.606. It is noteworthy that the current market trading price for the stock stands at $3.40. This represents a decline from its 52-week high of $7.14, yet it remains significantly elevated compared to its 52-week low of $2.19, having risen by 64% during that period.
The stated purpose for the sale was to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). Following this specific transaction, Mr. Wilson's direct holdings in Rocket Pharmaceuticals common stock were confirmed at 678,639 shares. These total holdings incorporate Restricted Stock Units that are convertible into common stock on a one-for-one basis.
Beyond the reported insider activity, ROCKET PHARMACEUTICALS, INC. has recently undergone several substantial financial and operational developments. The company announced the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million. This significant cash infusion is projected to extend the company's cash runway into the second quarter of 2028.
This voucher sale followed the U.S. Food and Drug Administration’s (FDA) accelerated approval of Kresladi, a gene therapy designed for severe pediatric patients suffering from leukocyte adhesion deficiency-I. The FDA granting this approval also provided Rocket Pharmaceuticals with a Priority Review Voucher, which was subsequently sold by the company.
The positive developments have prompted several external analysis firms to adjust their outlooks on RCKT. These adjustments reflect both the company’s ongoing progress and its strategic financial decisions. For instance, Leerink Partners revised its price target upward to $12.00 from a previous estimate of $11.00. They maintained a Market Perform rating while citing the voucher sale as a contributing factor to their adjustment.
Similarly, BofA Securities increased its price target to $9.00, up from $8.00. This firm upheld a Buy rating and specifically mentioned the company's execution during its recent call when providing this analysis.
In addition, Chardan reiterated its Buy rating and maintained a price target of $11.00 following the FDA’s approval of Kresladi. These multiple updates collectively highlight the company's trajectory based on key regulatory milestones and financial maneuvers.
From an analytical perspective, some sources suggest that RCKT may be undervalued at its current trading levels. An InvestingPro Tip highlighted that the company maintains more cash than debt on its balance sheet, which supports its classification of